Adverse events of grade 3 or higher were reported in 31 ( 37 % ) of 84 patients allocated cidofovir and 39 ( 46 % ) of 84 patients assigned imiquimod ; the most frequent grade 3 and 4 events were pain in the vulva , pruritus , fatigue , and headache .